Why CRISPR Therapeutics AG Jumped 11.7% in June – Motley Fool
Motley Fool |
Why CRISPR Therapeutics AG Jumped 11.7% in June
Motley Fool First, CRISPR and MaSTherCell SA announced that they have signed a development and manufacturing agreement related to allogeneic CAR-T therapies. The deal calls for MaSTherCell to handle the development and manufacturing of CRISPR’s compound … |
Madison.com |
Why CRISPR Therapeutics AG Jumped 11.7% in June
Madison.com First, CRISPR and MaSTherCell SA announced that they have signed a development and manufacturing agreement related to allogeneic CAR-T therapies. The deal calls for MaSTherCell to handle the development and manufacturing of CRISPR’s compound … CRISPR Therapeutics and Neon Therapeutics Enter Research CollaborationGlobeNewswire (press release) CRISPR Therapeutics teams up with Neon Therapeutics to develop T cell therapiesInvesting.com Crispr Theraptc (CRSP) Shares Sold by Clough Capital Partners LPSports Perspectives Transcript Daily all 6 news articles » |
Endpoints News |
Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program
Endpoints News After rattling investors with early signs of an immune reaction in a couple of cases as well as an unexpected infusion for a suspected knee bleed, Spark Therapeutics $ONCE says that its early Phase I/II study for its hemophilia B gene therapy is … |
|
Glioblastoma ‘ecosystem’ redefined for more effective immunotherapy trials
EurekAlert (press release) A research team has revealed the intrinsic gene expression patterns of glioblastoma (GBM) tumors, insights that could drive more effective treatments for GBM, the most common and deadly malignant primary brain tumors in adults. Jackson Laboratory (JAX) … |
|
Safety issues for Novartis CAR–T therapy main focus of FDA
BioPharma Dive The Food and Drug Administration plans to ask an independent panel of experts to focus their attention on the safety profile of Novartis’ experimental CAR–T therapy tisagenlecleucel when they meet to review the leukemia treatment at a public meeting … |
|
J&J drops stem cell partner Capricor
BioPharma Dive In a move resulting in an almost 10% dive of the smaller company’s share price, Johnson & Johnson has dumped its stem cell partner Capricor Therapeutics, deciding not to exercise its option for Capricor’s lead allogeneic cell-based product candidate … |